J&J MedTech sales miss in Q3 weighs on shares

Johnson & Johnson's MedTech division was the soft spot in its October 13 third-quarter report, even as the company beat profit estimates and lifted its 2026 outlook. MedTech sales grew 2.5% to about $8.64 billion, below the roughly $8.71 billion analysts had expected. Management said the division's underlying fundamentals remained strong despite the shortfall. Shares fell roughly 6% that day, the steepest one-day decline since April 2025, according to press coverage. Within MedTech, the company flagged weaker cardiovascular and Abiomed results, while Shockwave and Vision lines were cited as stronger.

1. Q3 2026 results were released October 13, 2026, with the company raising its full-year 2026 guidance.
2. MedTech Q3 sales rose 2.5% to about $8.64 billion versus roughly $8.71 billion expected by analysts.
3. Benzinga reported J&J shares fell about 6% on the results day, their steepest one-day drop since April 1, 2025.
4. On the call, the company said Shockwave grew 17% and Abiomed declined 1.5% in the quarter.
5. Management said it had not changed its ambition for MedTech despite falling short of expectations for the segment.